Imaging luciferase-expressing viruses

Methods in Molecular Biology

Volumn 797, Issue , 2012, Pages 79-87

  Barry, Michael A ^a,b   May, Shannon ^a   Weaver, Eric A ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Adenovirus; In vivo imaging; Luciferase; Luciferin; Luminescence

Indexed keywords

LUCIFERASE;

ADENOVIRUS; ANIMAL; ARTICLE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE TRANSFER; GENE VECTOR; GENETICS; HAMSTER; HUMAN; METHODOLOGY; MOLECULAR IMAGING; MOUSE; NEOPLASM; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CRICETINAE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, VIRAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LUCIFERASES; MICE; MOLECULAR IMAGING; NEOPLASMS; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; CRICETINAE; REPLICATION COMPETENT VIRUSES;

EID: 80555135975     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-340-0_6     Document Type: Chapter

References (11)

1. Blum, J. S., J. S. Temenoff, H. Park, J. A. Jansen, A. G. Mikos, and M. A. Barry. 2004. Development and characterization of enhanced green fluorescent protein and luciferase expressing cell line for non-destructive evaluation of tissue engineering constructs. Biomaterials 25:5809–5819.
2. Adams, K. E., S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. Sevick-Muraca. 2007. Comparison of visible and near-infrared wavelength excitable fluorescent dyes for molecular imaging of cancer. J Biomed Optics 12:024017-024011-024019.
3. Mok, H., D. J. Palmer, P. Ng, and M. A. Barry. 2005. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11:66–79.
4. Hofherr, S. E., S. Mok, F. C. Gushiken, J. A. Lopez, and M. A. Barry. 2007. Polyethylene Glycol Modification of Adenovirus Reduces Platelet Activation, Endothelial Cell Activation, and Thrombocytopenia. Human Gene Therapy 18:837–848.
5. Shashkova, E. V., K. Doronin, J. S. Senac, and M. A. Barry. 2008. Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer research 68:5896–5904.
6. Hofherr, S. E., E. V. Shashkova, E. A. Weaver, R. Khare, and M. A. Barry. 2008. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 16:1276–1282.
7. Weaver, E. A., and M. A. Barry. 2008. Effects of Shielding Adenoviral Vectors with Polyethylene Glycol (PEG) on Vector-specific and Vaccine-mediated Immune Responses. Hum Gene Ther 19:1369–1382.
8. Weaver, E. A., P. N. Nehete, S. S. Buchl, J. S. Senac, D. Palmer, P. Ng, K. J. Sastry, and M. A. Barry. 2009. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS ONE 4:e5059.
9. Shashkova, E. V., S. M. May, K. Doronin, and M. A. Barry. 2009. Expanded Anticancer Therapeutic Window of Hexon-modified Oncolytic Adenovirus. Mol Ther Online Sept 15.
10. Doronin, K., E. V. Shashkova, S. M. May, S. E. Hofherr, and M. A. Barry. 2009. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 20:975–988.
11. Chen, C. Y., S. May, and M. A. Barry. 2010. Targeting Adenoviruses with Factor X-Single Chain Antibody Fusion Proteins. Hum Gene Ther 21(6):739–749.